Clinical Trials
30 trialsNCT02808780 2026-05-08
OPAL
Janssen Biotech, Inc.
Active not recruiting
NCT05156125 2026-04-30
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma Ltd
Phase 2 Terminated
NCT03760003 2025-11-28
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Abivax S.A.
Phase 2 Completed
NCT05785715 2025-07-01
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie
Phase 2 Terminated
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT01804166 2025-02-04
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Janssen Scientific Affairs, LLC
Phase 4 Completed
NCT06583395 2024-11-01
QUANTUM
VitaMed Research LLC
Enrolling by invitation
NCT03710486 2024-05-30
EVOLVE-IBERIA
Takeda
Completed
NCT05635266 2024-05-07
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Recruiting
NCT01931644 2024-04-18
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Completed
NCT05579444 2023-12-15
Systems Biology of Gastrointestinal and Related Diseases
Viome
Terminated
NCT02136069 2021-12-03
GARDENIA
Hoffmann-La Roche
Phase 3 Completed
NCT02165215 2021-08-19
LAUREL
Hoffmann-La Roche
Phase 3 Completed
NCT02100696 2021-08-13
HICKORY
Hoffmann-La Roche
Phase 3 Completed
NCT02163759 2021-07-23
HIBISCUS I
Hoffmann-La Roche
Phase 3 Completed
NCT02171429 2021-07-23
HIBISCUS II
Hoffmann-La Roche
Phase 3 Completed
NCT02093663 2021-06-09
PACE
Takeda
Phase 3 Completed
NCT03452501 2021-02-23
Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
Hikma Pharmaceuticals LLC
Completed
NCT01805791 2020-01-02
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
Hutchmed
Phase 3 Terminated
NCT01959282 2019-01-04
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC
Phase 2 Completed
NCT03090139 2018-06-26
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
Takeda
Completed
NCT00663819 2018-04-17
Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses
W.L.Gore & Associates
Phase NA Terminated
NCT02092389 2017-02-23
AdaProQuo
AbbVie
Terminated
NCT00659867 2016-09-27
Endomicroscopy in Ulcerative Colitis
PENTAX Europe GmbH
Phase NA Terminated
NCT01002287 2014-11-20
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery
Integra LifeSciences Corporation
Phase NA Terminated
NCT01759056 2014-03-05
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
Avaxia Biologics, Incorporated
Phase 1 Completed
NCT01880918 2013-06-19
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
novoGI
Unknown
NCT01301417 2013-06-05
RETROPRESS
novoGI
Completed
NCT00727324 2012-04-02
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis
AM-Pharma
Phase 2 Completed
NCT00676832 2010-09-29
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
Prometheus Laboratories
Phase 2 Completed